Target intelligence / Profile preview

Liver detoxification pathways

Molecular classification
Enzyme systems (most notably cytochrome P450s, various transferases), Other (pathway/process, not a single molecule)
01

Overview

Liver detoxification pathways describe the series of enzymatic processes, primarily occurring in the liver, that convert lipophilic substances—including drugs, xenobiotics, and metabolic byproducts—into more hydrophilic metabolites for excretion. This system is broadly categorized into Phase I (functionalization, mainly via cytochrome P450s) and Phase II (conjugation, such as glucuronidation, sulfation, acetylation, glutathione, and amino acid conjugation), which sequentially process toxicants. Phase I generates intermediate metabolites, some of which can be more reactive and potentially harmful, while Phase II reactions generally further increase hydrophilicity and facilitate excretion via urine or bile. These pathways are regulated by nuclear receptors and are critical for drug metabolism, protection against environmental toxins, and prevention of cellular damage, but can also contribute to disease states if dysregulated or genetically impaired.

Other names
Hepatic biotransformation pathwaysPhase I and Phase II detoxificationLiver metabolic detoxification
02

Mechanism of action

Induction or inhibition of Phase I or Phase II enzyme activity Alteration of metabolic rates for co-administered drugs

03

Biological functions

Xenobiotic metabolismDetoxification of toxins (drugs, environmental chemicals, endogenous metabolites)Protection against oxidative stressConjugation of waste metabolites for excretion
04

Disease associations

Liver disease (such as cholestasis, cirrhosis, fatty liver)Drug toxicity/overdoseCancer (altered metabolism affecting susceptibility)Other (susceptibility to environmental toxins)
05

Safety considerations

Formation of toxic intermediates (e.g., reactive oxygen species, electrophilic metabolites)Drug-drug interactions due to competition for or inhibition/induction of detox enzymesGenetic polymorphisms affecting drug metabolism and susceptibility to adverse effects
06

Interacting drugs

Inhibitors and inducers of liver enzymes (e.g., rifampin, phenobarbital induce P450s; ketoconazole inhibits certain P450s)

1 more in the full profile.

07

Biomarkers

Enzyme activity assays (e.g., CYP450 activity)Conjugated vs. unconjugated metabolite ratiosGlutathione levelsLiver function tests (ALT, AST as proxies)

Beyond the preview

Go deeper on Liver detoxification pathways.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liver detoxification pathways.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call